Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients

Value of FLT PET/CT in Radium-223 Therapy of Patients With Metastatic Castration-resistant Prostate Cancer

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03011749

Enrollment

Registered

2017-01-05

Start date

2017-01-31

Completion date

2018-02-28

Last updated

2019-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Prostate Carcinoma

Keywords

Radium-223 therapy

Brief summary

The aim of the study is to investigate whether positron emission tomography (PET) using the tracer 18F-Fluorothymidine (FLT) can provide information on proliferative activity in bone marrow of patients receiving Radium 223 therapy and potentially be a predictive marker of hematological toxicity

Interventions

OTHERFLT PET/CT

FLT PET/CT before first series of Radium-223 and after 2 series

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

MALE

Healthy volunteers

Inclusion criteria

* Metastatic castration resistant prostate cancer * Eligible for Radium-223 therapy * Informed consent

Exclusion criteria

* Inability to understand study protocol * Extensive metastatic involvement of the axial skeleton (superscan on bone scintigraphy)

Design outcomes

Primary

Measure	Time frame
Uptake of FLT in hematological bone marrow	3 months

Secondary

Measure	Time frame
Occurrence of hematological toxicity	12 months

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026